Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Neoplasms × Tyrosine Kinase Inhibitors × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 3 Carcinoma, Renal Cell 2 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 NSCLC 1 Liver Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Biphenotypic, Acute 1 Kidney Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Paclitaxel 115 Carboplatin 115 Bevacizumab 76 Gemcitabine 38 pembrolizumab 36 olaparib 32 Cisplatin 27 Docetaxel 26 Cyclophosphamide 26 niraparib 25 liposomal doxorubicin 23 Topotecan 22 Etoposide 17 Doxorubicin 15 Taxes 13 apatinib 12 Letrozole 12 Immunoglobulin G 11 Filgrastim 11 Drug Therapy 11 Disulfides 11 Albumin-Bound Paclitaxel 11 fludarabine 10 fluzoparib 9 Biopsy 9 durvalumab 8 Specimen Handling 8 Nivolumab 8 Magnetic Resonance Spectroscopy 8 Cytoreduction Surgical Procedures 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03314740 2025-01-10

BAROCCO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡